The SVM model composed of ARID1A, GTF2H2, and PRKRIR yielded a sensitivity of 91.3% and a specificity of 85.2% for ESCC in the training cohort (Figures 2A, E) and a sensitivity of 87.5% and a specificity of 81.1% in the validation cohort (Figures 2B, F). Here, THAP12 is linked to esophageal squamous cell carcinoma.